Business
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
BEIJING, May 22, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the abstracts of two clinical studies of the Company's novel BCL2 inhibitor mesutoclax have been published on the official website of the American Society of Clinical Oncology (ASCO). The study of mesutoclax for the treatment of myeloid malignancies was selected for an oral presentation at this
About this update from Innocare Pharma Ltd. Class A
[{"type":"image","alt":"InnoCare Pharma","displaySize":"","headline":null,"caption":"InnoCare Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/1885e93031454229063957b3a9d6b6ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TUcpUGfHDeiONwDdqJpdzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Mg--/https://media.zenfs.com/en/globenewswire.com/1885e93031454229063957b3a9d6b6ec","width":300,"height":116},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/TUcpUGfHDeiONwDdqJpdzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Mg--/https://media.zenfs.com/en/globenewswire.com/1885e93031454229063957b3a9d6b6ec","width":300,"height":116}},"lazy":false},{"type":"text","content":"BEIJING, May 22, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the abstracts of two clinical studies of the Company's novel BCL2 inhibitor mesutoclax have been published on the official website of the American Society of Clinical Oncology (ASCO). The study of mesutoclax for the treatment of myeloid malignancies was selected for an oral presentation at this year's ASCO annual meeting, and the research on mesutoclax for B-cell malignancies was chosen for a poster presentation.","length":628,"tagName":"p"},{"type":"text","content":"The following data has just been released on the ASCO official website, with updated oral presentation data to be announced on June 2 Central Time. The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies.","length":268,"tagName":"p"},{"type":"text","content":"Oral Presentation","length":17,"tagName":"p"},{"type":"text","content":"Safety, tolerability, and efficacy of mesutoclax (ICP-248) in combination with azacitidine in patients with myeloid malignancies (Abstract No.: 6506)","length":149,"tagName":"p"},{"type":"text","content":"The study enrolled patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Mesutoclax has demonstrated favorable safety and efficacy in the treatment of both MDS and AML.","length":193,"tagName":"p"},{"type":"text","content":"Among evaluable treatment-naïve (TN) MDS patients, the overall response rate (ORR) per IWG 2006 c...